Add to a list

Inactive Instrument

Checkmate Pharmaceuticals, Inc. Stock

CMPI

US1628181083

Biotechnology & Medical Research

Latest news: Checkmate Pharmaceuticals, Inc.

02/06/22	Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	MT
02/06/22	Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	MT
31/05/22	Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer	CI
31/05/22	Checkmate Pharmaceuticals, Inc. Announces Board Changes	CI
31/05/22	Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index	CI
31/05/22	Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index	CI
27/05/22	Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	CI
27/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	CI
13/05/22	Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
27/04/22	Kuros Biosciences' Q1 Medical Devices Sales Surge 102% Following US FDA Approval For MagnetOs	MT
20/04/22	BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	MT
20/04/22	Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets	MT
20/04/22	Top Midday Gainers	MT

More news

Analysts' recommendations: Checkmate Pharmaceuticals, Inc.

20/04/22	BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	MT
31/03/22	BTIG Adjusts Checkmate Pharmaceuticals' Price Target to $9 from $29, Keeps Buy Rating	MT
06/10/21	Checkmate Pharmaceuticals : BofA Securities Upgrades Checkmate Pharmaceuticals to Buy From Neutral, Price Target at $7	MT

More recommendations

Press Releases: Checkmate Pharmaceuticals, Inc.

02/06/22	Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment	AQ
31/05/22	Checkmate Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	PU
31/05/22	CHECKMATE PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
27/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
27/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	GL

More press releases

News in other languages: Checkmate Pharmaceuticals, Inc.

03/06/22	Bourse Zurich: rebond technique, le SMI finit au-dessus des 11'500 points
02/06/22	Bourse Zurich: dans le vert, à la faveur d'un rebond technique
02/06/22	Kuros reçoit un paiement d'étapes après la cession de Checkmate
02/06/22	Kuros erhält durch Checkmate-Übernahme Meilensteinzahlung von 5 Mio USD
16/03/22	Kuros Biosciences double ses revenus issus des produits en 2021

More news

Managers and Directors: Checkmate Pharmaceuticals, Inc.

Manager	Title	Age	Since
Barry A. Labinger CEO	Chief Executive Officer	62	12/12/2018
Robert Landry DFI	Director of Finance/CFO	62	31/05/2022
James Wooldridge CTO	Chief Tech/Sci/R&D Officer	60	01/10/2019

Director	Title	Age	Since
Nouhad Husseini BRD	Director/Board Member	-	31/05/2022

More insiders

Checkmate Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. The Company's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The Company is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The Company is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The Company's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
CMPI Stock

As early as today, start finding the best investment opportunities!

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/5/22	Keith Flaherty	Issuer sale	Director	36,778	0.1700%
31/5/22	Robert Dolski	Issuer sale	Chief Financial Officer	278,480	1.2874%
31/5/22	Alan Fuhrman	Issuer sale	Chief Executive Officer	279,437	1.2919%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHECKMATE PHARMACEUTICALS, INC.	-.--%	+0.38%	-	-	231M
WUXI APPTEC CO., LTD.	-6.60%	-8.56%	+49.38%	+63.51%	65B
LONZA GROUP AG	+0.03%	+5.56%	+9.10%	+69.05%	51.2B
ARGENX SE	-4.09%	-0.11%	+2.22%	+53.15%	51.19B
IQVIA HOLDINGS INC.	-1.53%	+2.70%	+30.48%	+34.12%	43.93B
BEONE MEDICINES AG	-1.34%	+4.12%	+16.64%	+115.13%	41.96B
REVOLUTION MEDICINES, INC.	-5.97%	-6.22%	+228.95%	+454.22%	38.14B
CELLTRION, INC.	+6.53%	+8.02%	+16.40%	+53.41%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	-3.70%	25.2B
GENMAB A/S	-1.07%	+2.33%	+19.43%	+9.98%	22.5B
Average	-1.49%	-0.35%	+45.52%	+94.32%	41.37B
Weighted average by Cap.	-2.19%	-0.50%	+44.25%	+96.53%

Checkmate Pharmaceuticals, Inc. Stock

Stocks

CMPI

US1628181083

Biotechnology & Medical Research

Latest news: Checkmate Pharmaceuticals, Inc.

Analysts' recommendations: Checkmate Pharmaceuticals, Inc.

Press Releases: Checkmate Pharmaceuticals, Inc.

News in other languages: Checkmate Pharmaceuticals, Inc.

Managers and Directors: Checkmate Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile